Phaarmasia
BSE: PHRMASI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Phaarmasia's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Phaarmasia Limited is a Hyderabad-based pharmaceutical company operating primarily as a contract research and manufacturing organisation. It specialises in producing diverse formulations, including tablets, capsules, ointments, and creams, with a focus on dermatology, anti-infectives, and lifestyle diseases.
Business Model
The company generates revenue by providing outsourced manufacturing and research services to larger pharmaceutical entities. It leverages its Telangana-based facility to serve both domestic and international markets.
Growth Outlook
Growth is driven by the company's niche presence in the small-cap pharmaceutical sector and its strategic association with the Maneesh Pharmaceuticals group. The firm continues to focus on expanding its manufacturing capabilities to meet international quality standards.
Key Risks
- Regulatory Compliance. Failure to maintain international quality standards at manufacturing facilities could lead to loss of export contracts and reputational damage.
- Client Concentration. As a contract manufacturer, the company is highly dependent on the outsourcing requirements and commercial success of its larger pharmaceutical clients.
- Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, which may exert pressure on margins for contract manufacturing services.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact the company's operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Phaarmasia and 5,000+ companies — free.
Key Metrics
REVENUE
₹47 Cr
TTM · standalone
NET PROFIT
₹19 Cr
TTM · standalone
EPS
₹27.81
TTM · standalone
RETURN ON EQUITY
157.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
184.6%
TTM · standalone
P/E
3.6x
Q4 FY26 · standalone
EV/EBITDA
17.7x
Q4 FY26 · standalone
EBITDA MARGIN
8.3%
TTM · standalone
NET PROFIT MARGIN
9.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
PhaarmasiaPHRMASI | ₹65 Cr | 3.44 | 16.90 | 93.7% | 8.3% | 157.1% | 184.6% | +179.6% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Phaarmasia
BSE: PHRMASI · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Phaarmasia's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Phaarmasia Limited is a Hyderabad-based pharmaceutical company operating primarily as a contract research and manufacturing organisation. It specialises in producing diverse formulations, including tablets, capsules, ointments, and creams, with a focus on dermatology, anti-infectives, and lifestyle diseases.
Business Model
The company generates revenue by providing outsourced manufacturing and research services to larger pharmaceutical entities. It leverages its Telangana-based facility to serve both domestic and international markets.
Growth Outlook
Growth is driven by the company's niche presence in the small-cap pharmaceutical sector and its strategic association with the Maneesh Pharmaceuticals group. The firm continues to focus on expanding its manufacturing capabilities to meet international quality standards.
Key Risks
- Regulatory Compliance. Failure to maintain international quality standards at manufacturing facilities could lead to loss of export contracts and reputational damage.
- Client Concentration. As a contract manufacturer, the company is highly dependent on the outsourcing requirements and commercial success of its larger pharmaceutical clients.
- Market Competition. The Indian pharmaceutical sector is highly fragmented and competitive, which may exert pressure on margins for contract manufacturing services.
- Input Cost Volatility. Fluctuations in the prices of active pharmaceutical ingredients and raw materials can significantly impact the company's operational profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Phaarmasia and 5,000+ companies — free.
Key Metrics
REVENUE
₹47 Cr
TTM · standalone
NET PROFIT
₹19 Cr
TTM · standalone
EPS
₹27.81
TTM · standalone
RETURN ON EQUITY
157.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
184.6%
TTM · standalone
P/E
3.6x
Q4 FY26 · standalone
EV/EBITDA
17.7x
Q4 FY26 · standalone
EBITDA MARGIN
8.3%
TTM · standalone
NET PROFIT MARGIN
9.1%
Q4 FY26 · standalone
DEBT TO EQUITY
0.1x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26